Hepatitis C is an ailment of the liver, brought about by a viral infection (hepatitis C virus - HCV). The infection is transmitted via bodily fluids and blood in particular. Though unprotected sexual contact poses a risk, little evidence of sexual transmission is available. The condition is asymptomatic for a brief initial period, followed by vague symptoms such as low fever, yellow skin, dark urine etc. Thus, the condition is hard to notice in the initial stage, with people become aware of their ailment and attaining a diagnosis late in the infection – all the while acting as carriers and transmitting the infection forward. HCV infection has a mortality rate of 1%, with the morbidity (liver cancer and cirrhosis) rate being much higher [1,2]. More than 10 million people in Pakistan are afflicted with the condition, entailing a high morbidity and mortality.

According to a comprehensive systematic review (based on literature published from 1994 to 2009), “prevalence of HCV was (4.95%± 0.53%) in the general adult population, (1.72%± 0.24%) in the pediatric population and (3.64%± 0.31%) in a young population, whereas a very high (57%± 17.7%) prevalence was observed in injecting drug users and (48.67%± 1.75%) in a multi-transfused population [3-5].

Tumor markers are biomolecules found in blood, urine and tissue of individuals and, with particularly high concentration in most cancers, therefore, their concentration has diagnostic value. These markers may be used for screening, identification (type and stage), monitoring, and predicting prognosis. Increases in tumor markers are sometimes seen in patients with chronic liver disease without hepatocellular carcinoma (HCC).

**Objective:** To determine the tumor markers, present among patients with Hepatitis C Infection.

**Methods:** From April 2021 to March 2022, serum samples from 700 HCV patients who presented to the Department of Pathology at the Pir Syed Abdul Qadir Shah Jeelani Institute of Medical Sciences, Gambat Khairpur Mirs, were used in this descriptive, cross-sectional study. Using the ACCESS-2 system, serum samples were analyzed for the presence of the specified tumor markers.

**Results:** There was a significant increase in CA125 (P = 0.03) and AFP levels (P = 0.03). CA19-9, CEA, and CA15-3 levels in the blood were unremarkable (P > 0.05). It is too early to say if the increase in CA125 or AFP will lead to eventual carcinoma based on this study, but it deserves further exploration using a longitudinal research methodology.

**Conclusion:** CA125 and AF (P were the most common tumor markers found in HCV patients. Given the association of the aforementioned indicators with hepatic cancer, HCV patients with CA125 and AFP levels over normal should be considered high-risk.

**Key Words:** HCV, Tumor Marker, Liver Cancer, Biomarker, CA19-9, CA125, CA15-3 and AFP

**How to Cite:**
Bhatti, S., Saeed, A., Ahuja, K., Memon, K., . ., Khatoon Bhatti, N., . & Qasim Ujjan, G. . (2022). Evaluation of Tumor Markers Among Patients with Hepatitis C Infection. Pakistan Biomedical Journal, 5(5). https://doi.org/10.54393/pbmj.v5i5.475

Received Date: 21st May, 2022
Acceptance Date: 27th May, 2022
Published Date: 31st May, 2022
concentration in most cancers, therefore, their concentration has diagnostic value [6,7]. These markers may be used for screening, identification (type and stage), monitoring, and predicting prognosis of cancer [8,9]. Patients with chronic liver illness but no hepatocellular carcinoma may see an increase in tumor markers (HCC). This could be a sign of imminent cancer and thus an opportunity to intervene quickly, avoiding a poor outcome and gaining a favorable prognosis. The goal of this study was to evaluate the levels of tumor markers in patients with Hepatitis C infection in order to identify HCV carriers who are at high risk for cancer development.

**Alpha Fetoprotein (AFP):** This fetal specific glycoprotein is primarily developed in the fetal liver. In normal circumstances the serum concentration of AFP falls immediately following the birth and thereafter, all production is repressed. It has been noted that out of every 10 HCC patients have elevated levels of AFP in the serum (attributed to secretion by the tumor). To date, serum AFP is regarded as the tumor marker that is most useful in screening HCC among suspected patients. Commonly, a serum concentration of 30 ng/mL is deemed a differentiation point or a cut-off value between normal individual and HCC patients (Sensitivity:65% and Specificity:89%).[10].

**CA 15-3:** Secreted by normal cells in the breast, this murine monoclonal antibody (molecular weight: 300–450 kDa) is particularly elevated among patients with cancerous tumors (in the breast and/or elsewhere). The point of differentiation between healthy and diseased (cancerous) individuals is a concentration is 25 U/ml for CA 15-3. The marker is also known to be elevated among conditions other than hepatocellular carcinoma, such as cancer of the lungs, colon, rectum, and breast.[11].

**CA 19-9:** The carbohydrate antigen 19-9 (CA19-9) is a known marker for illness states such as colon cancer and gastrointestinal adenocarcinoma. The point of differentiation between healthy and diseased (cancerous) is a concentration of more than 37 U/mL in addition to hepatocellular carcinoma, the serum concentrations of this marker are also noted among patients with cancer of the stomach, lungs, colon, and pancreas.[12].

**CA 125:** This carbohydrate–related high molecular mass glycoprotein (molecular weight: >200 kDa) marker is a carbohydrate antigen that can be found in up to 80% of non-mucinous ovarian cancer cases. The marker is primarily a monoclonal antibody. The point of differentiation between healthy and disease (cancerous) cases is a serum concentration of an upwards of 35 U/mL in addition to hepatocellular carcinoma, the serum concentration of CA125 is elevated among patients with cancer of the lungs, endometrium, pancreas, breast, and colon [13,14]. CEA: This antigen is an oncofetal antigen that is linked to a wide group of cell surface glycoproteins (molecular weight: 150–300 kDa) that are found on numerous cell types but have much higher concentrations in tumour patients and fetuses (normal). Smokers and nonsmokers have various points of differentiation (between normal and ill persons), namely 2.5g/l and 5.0g/l, respectively.

**METHODS**

This descriptive, cross-sectional study was conducted from April 2021 to March 2022 using serum samples of 700 HCV patients, presenting to the Dept. of Pathology at Pir Syed Abdul Qadir Shah Jeelani Institute of Medical Sciences, Gambat, Khairpur Mirs. The serum samples were checked for the existence of the listed tumor markers by ELISA using ACCESS-2 machine. ACCESS-2 can identify the following prominent biomarkers, among others. Since the levels (obtained via biochemical tests) of biomarkers can vary with time and between patients, the principles of best practice state that an arithmetic mean be used. Inclusion criteria was confirmed cases of HCV. Exclusion criteria was patients receiving hepatitis medication / Antiviral Therapy, Interferon-alpha (Subcutaneous Inj.) in combination oral Ribavirin & Lamivudine. Proven cases of hepatocellular carcioma(HCC).

**RESULTS**

The mean age of the sample stood at 43 (SD±3) years, with most of the sample comprising of males (59.29%), and the remaining being females (40.71%). Patients (73.14%) hailed from an urban setting while the remaining had a rural (26.86%) residence. A summary of the sociodemographic characteristics of the sample population are tabulated below. An increase in CA125 and AFP levels, was noted. Levels (in serum) of tumor marker CA15-3, CA19-9, and CEA were unremarkable.

| Variables          | Statistical – n(%) |
|--------------------|--------------------|
| **Age (Years)**    |                    |
| Up to 20           | 92 (13.14%)        |
| 21 to 30           | 103 (14.71%)       |
| 31 to 40           | 175 (25.25%)       |
| 41 to 50           | 161 (23.23%)       |
| 51 and above       | 94 (13.43%)        |
| 41 to 45           | 75 (10.72%)        |
| **Gender**         |                    |
| Male               | 415 (59.29%)       |
| Female             | 285 (40.71%)       |
| **Residence**      |                    |
| Urban              | 512 (73.14%)       |
| Rural              | 198 (26.86%)       |
| **Educational Status** |                  |
| Educated           | 404 (57.71%)       |
| Un-Educated        | 296 (42.29%)       |
### DISCUSSION

A variety of markers are used for HCC and among the said markers is serum alpha-fetoprotein (AFP), which is used widely and with great effect. However, it is noted that serum AFP levels are oftentimes increased among patients with ailments of the liver other than HCC. The same conditions may also infect patients concurrently with HCV in up to 42% of the cases, putting the specificity of AFP (with regards to HCV) into doubt [15]. In this research, an 85% of the sample population had a raised AFP level. Research suggests that the hiked levels of AFP result from hepatocyte destruction (due to viral hepatitis) and consequent attempts of regeneration [16]. Recently, more alternatives have surfaced that outperform AFP in terms of specificity for HCC, [17] such as the “Lens culinaris agglutinin-reactive fraction of AFP (AFP-L3%)” [12] and “des-c-carboxy prothrombin (DCP)” [18]. The Access-2 machine used in this research does not measure the said markers, which is synonymous with the existing literature [23,24]. It may thus be safe to state that patients with hepatitis may have elevated levels of CEA in the absence of a tumor / cancer. However, CEA levels may rather be more efficacious for purposes pertaining to management of the disease condition [25]. This study did have a few limitations. Firstly, it was a single center study and although the setting played host to a diverse demographic cohort, it is still a possibility that the results may not be truly generalizable to the general population. Nonetheless, care was exercised in extrapolating the study findings to other populations.

### CONCLUSIONS

After careful consideration and a thorough evaluation CA125 and AFP were the prominent tumor markers detected among patients with hepatitis C. Keeping in view the co-occurrence of the said markers with hepatic carcinoma, it is advised that hepatitis C patients with CA125 and AFP levels above normal may be treated as high-risk patients.

### REFERENCES

1. Dennis LK, Eugene Stephen H, Dan L, J Larry J, Anthony SF. Harrison's principles of internal medicine. 16th ed Mc Graw-Hill, New York,2004;1855–80.
2. Cohan N, Zandieh T, Samiei SH, Ataie Z, Kavari M. The prevalence and clinical significance Hepatitis B and C co-infection. Iran J Sci, 2006;31(3):156–159.
3. Lok As, McMahon B. Chronic hepatitis B. Hepatology, 2001;34(6):1225–1241. doi.org/10.1053/jhep.2001.29401
4. Massarat MS, Tahaghoghi mehrizi S. Iranian national health survey: a brief report. Arch Iran Med, 2002;5(2):73–79.
5. Alaviani SM, Follahian F, Bagheri lankarani K. The changing epidemiology of viral Hepatitis Bin Iran 2007:16(4):403–6.
6. Pour shams A, Nasiri J, Mohammad khani A, Nasrollahzadeh D. Hepatitis B in Gonbad-kavvos: prevalence, risk factors and interfamilial spreading. Govaresh, Iran Hepatol, 2004; 4(9):222–5.
7. Hosseini ASI, Avijan M, Mohammad nejhad M. High prevalence of HBV, HCV, HIV infection gypsy...
population residing in Shahr-e-kord. Aech Iran Med, 2004;7(1): 20–22.

[8] Zali MR, Mohammad K, farhadi Ad, Masjedi MR, zargar A, Nawroozi A. Epidemiology of hepatitis B in the Islamic Republic of Iran. East Mediterr Health J,1996; 2(2): 290–

[9] Johnson RJ, Couser WG. Hepatitis B infection and renal diseases: clinical, immunopathogenetic and therapeutic considerations. Kidney Int, 1990;37: 663. doi.org/10.1038/ki.1990.32

[10] Daniel WC, Stewart S. Tumour markers. In: Burtis CA, Ashwood ER, editors. Teitz textbook of clinical chemistry 3rd edn. Philadelphia: Saunders Elsevier; 1999;733–737.

[11] Shitrit D, Zingerman B, Shitrit AB, Shlomi D, Kramer MR. Diagnostic value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 assays in pleural effusions: analysis of 116 cases and review of the literature. Oncologist. 2006; 10:501–507. doi.org/10.1634/theoncologist.10-7-501

[12] Pasaoglu G, Zamani A, Can G, Imecik O. Diagnostic value of CEA, CA19-9, CA 125 and CA 15-3 levels in malignant pleural fluids. Eur J Gen Med. 2007;4(4):165–171. doi.org/10.29333/ejgm/82523

[13] Ghosh I, Bhattacharjee D, Das AK, Chakrabarti G, Dasgupta A, Dey SK. Diagnostic role of tumour markers CEA, CA15-3, CA19-9 and CA125 in lung cancer. Indian J Clin Biochem. 2013 Jan;28(1):24-9. doi.org/10.1007/s12291-012-0257-0

[14] Yang X, Wang D, Yang Z, Qing Y, Zhang Z, Wang G, et al. CEA is an independent prognostic indicator that is associated with reduced survival and liver metastases in SCLC. Cell Biochem Biophys. 2011;59(2):113–119. doi.org/10.1007/s12013-010-9121-0

[15] Jihadi AA, Avijgan M, Hafizi M. Prevalence of HBV and HCV infections and associated risk factors in addict prisoners. Iran J Public Health, 2006;35: 33–6.

[16] Shi J, Su Q, Zhang G, Huang G, Zhu Y. An intelligent decision support algorithm for diagnosis of colorectal cancer through serum tumor markers. Comput Methods Prog Biomed, 2010;100: 97–107. doi.org/10.1016/j.cmpb.2010.03.001

[17] Gadducci A, tana R, Cosio S, Genazzani AR. The serum assay of tumor markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer. Crit Rev Oncol Hematol, 2008;66: 10–20. doi.org/10.1016/j.critrevonc.2007.09.002

[18] Motoo Y, Satomura Y, Mouri I. Serum levels of pancreatitis-associated protein in digestive diseases with special reference to gastrointestinal cancers. Dig Dis Sci,1999; 44: 1142–47.doi.org/10.1023/A:1026620006078

[19] Maaestranzi S, Przemioslo R, Mitchel H. The effect of benign and malignant liver disease on the tumor markers CA19-9 and CEA. Ann Clin Biochem,1998; 35: 99–103. doi.org/10.1177/000456329803500113

[20] Derarbhavi H, Kaese D, William AW. Cancer antigen 125 in patients with chronic liver diseases. Mayo Clin Proc, 2002;77: 538–41.doi.org/10.4065/77.6.538

[21] Canney PA, Moore M, Wilkinson PM. Ovarian cancer antigen CA125: A prospective clinical assessment of its role as a tumor marker. Br J Cancer, 1984;50: 765–9. doi.org/10.1023/A:1026620006078

[22] Molina R, Filella X, Bruix J. Cancer antigen 125 in serum and ascetic fluid of patients with liver diseases. Clin Chem, 1991;37: 1379–83.doi.org/10.1093/clinchem/37.8.1379

[23] George PK, Lowenstein MS, Brien MJ. Circulating CEA levels in patients with fulminant hepatitis. Dig Dis Sci, 271982; 139 –142.doi.org/10.1007/BF01311707

[24] Maaestranzi S, Przemioslo R, Mitchel H. The effect of benign and malignant liver disease on the tumor markers CA19-9 and CEA. Ann Clin Biochem, 1998; 35: 99–103. doi.org/10.1177/000456329803500113

[25] Assmar M, Yeganeh S, Mansourghanaei F, Amirmozafari N. Combined evaluation of AFP, CA15-3, CA125, CA19-9, and CEA tumor markers in patients with hepatitis B and C. Iranian journal of public health. 2016 Dec;45(12):1645.